Skip to Content

Generic Fusilev Availability

Fusilev is a brand name of levoleucovorin calcium, approved by the FDA in the following formulation(s):

FUSILEV (levoleucovorin calcium - powder;iv (infusion))

  • Manufacturer: SPECTRUM PHARMS
    Approval date: March 7, 2008
    Strength(s): EQ 50MG BASE/VIAL [RLD] [AP]

FUSILEV (levoleucovorin calcium - solution;iv (infusion))

  • Manufacturer: SPECTRUM PHARMS
    Approval date: April 29, 2011
    Strength(s): EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML), EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

Has a generic version of Fusilev been approved?

A generic version of Fusilev has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Fusilev and have been approved by the FDA:

levoleucovorin calcium powder;iv (infusion)

  • Manufacturer: WEST-WARD PHARMS INT
    Approval date: June 16, 2016
    Strength(s): EQ 50MG BASE/VIAL [AP]

Note: No generic formulation of the following product is available.

  • levoleucovorin calcium - solution;iv (infusion)

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fusilev. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Substantially pure diastereoisomers of tetrahydrofolate derivatives
    Patent 6,500,829
    Issued: December 31, 2002
    Inventor(s): Hamish Christopher Swan; Wood & Colin James; Suckling & Lilias G.; Rees
    Assignee(s): University of Strathclyde
    The present invention related to the preparation of substantially pure diastereoisomers of derivatives of tetrahydrofolate and the use of such diastereoisomers. More particularly the present invention provides a process for the preparation of a desired substantially pure (6R or 6S) diastereoisomer of a derivative of tetrahydrofolic acid or salt or ester. The process comprises the steps of: attaching a chiral auxiliary group at either N-5 or N-10 of a mixture of 6R and 6S diastereoisomers of tetrahydrofolic acid, separating the new diastereoisomers, recovering the desired new diastereoisomer (6R or 6S) corresponding to the desired (6R or 6S) diastereoisomer, and converting the substantially pure new diastereoisomer recovered into the corresponding diastereoisomer.
    Patent expiration dates:
    • March 7, 2022
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • April 29, 2018 - ORPHAN DRUG EXCLUSIVITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
APInjectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.
Hide